BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer's Disease

26.06.2023 - Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the American Diabetes Association Annual MeetingCARSON CITY, Nev., June 26, 2023 (GLOBE NEWSWIRE) - BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company ...

Related Keywords

Gothenburg ,Vastra Gotalands Lan ,Sweden ,United States ,Americans ,Bruce Mackle ,Mann Whitneyp Pabout Biovie ,K Biovie Inc ,International Conference On Alzheimer ,Biovie Inc ,Nasdaq ,Metabolic Dysregulation ,Probable Alzheimer ,Christopher Reading ,Clinical Trial ,International Conference ,Related Neurological Disorders ,Investor Relations Inquiries ,Biovie Registereda ,